Diagnostic approaches and potential therapeutic options for coronavirus disease (COVID-19)

dc.creatorKhan, Zafran
dc.creatorGhafoor, Dawood
dc.creatorKhan, Asaf
dc.creatorUaliyeva, Daniya
dc.creatorAkbar Khan, Shahzad
dc.creatorBilal, Hazrat
dc.creatorKhan, Babar
dc.creatorKhan, Ayub
dc.creatorSajjad, Wasim
dc.date.accessioned2020-10-06T19:38:09Z
dc.date.available2020-10-06T19:38:09Z
dc.date.created2020
dc.description.abstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of China in late December 2019 and identified as a novel coronavirus. Due to its contagious nature, the virus spreads rapidly and causes coronavirus disease 2019 (COVID-19). The global tally of COVID-19 spikes 28 million. The fears and stress associated with SARS- CoV-2 demolished the socio-economic status all over the world. Researchers are trying around the clock to find out the treatment especially antiviral drugs and/or vaccines that could potentially control the viral spread and manage the ongoing unprecedented global crises. To date, more than 300 clinical trials have been conducted on various antiviral drugs, and immunomodulators are being evaluated at various stages of COVID-19. This review is aimed to collect and summarize a list of drugs used to treat COVID-19 for instance, dexamethasone, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide, and ivermectin. However, some of these drugs are not effective and suspended by the WHO (World Health Organization).spa
dc.format.extent38 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.nmni.2020.100770spa
dc.identifier.issn2052-2975spa
dc.identifier.otherhttps://doi.org/10.1016/j.nmni.2020.100770spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/14270
dc.language.isoengspa
dc.publisherNew Microbes and New Infectionsspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS- CoV-2spa
dc.subjectCOVID-19spa
dc.subjectWHOspa
dc.subject2019-nCoVspa
dc.subjectDrugsspa
dc.subjectGlobal tallyspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleDiagnostic approaches and potential therapeutic options for coronavirus disease (COVID-19)spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: